Clinical Trial

Role of Finerenone in African American Veterans With Diabetic Kidney Disease

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
Primary Objectives: To study podocyte specific injury markers (podocyte specific proteins, PSP) nephrin, podocalyxin and Wilms'Tumor (WT-1) protein in exosomes urine from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease (DKD), using Empagliflozin or Finerenone or combination therapy. Secondary Objectives: (1). Correlate changes in exosome-based PSP with standardized biomarkers of kidney injury including urine albumin/creatinine ratio (ACR) and estimated GFR. (2) with systemic inflammatory markers (focusing on vascular and endothelial function) that are already established such as interleukins (IL1, IL6, IL-12), hs-CRP and (3) arterial stiffness measures and with (4) APOL1 mRNA expression levels in peripheral blood derived mononuclear cells (MNC).
Trial Details
NCT Number NCT07155694
Lead Sponsor Washington D.C. Veterans Affairs Medical Center
Collaborators: Bayer
Conditions Diabetic Kidney Disease
Enrollment 30 participants
Start Date 2025-09
Primary Completion 2027-07 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2025-09-04